Cyprotex, the pharmaceuticals company specialising in the adverse effects of chemicals on living organisms, has signed a collaborative research agreement with US pharmaceuticals giant Pfizer.
The two parties will evaluate, further develop, and improve several of Cyprotex's proprietary offerings in the area of predictive toxicology.
The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction. Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients," said Dr Anthony Baxter, Cyprotex's Chief Executive Officer.
-
High pension fees could take £70k from your retirement pot – time to check what you’re payingEight out of 10 savers have no idea what fees they are paying to their pension provider to manage their retirement fund, and these charges can vary wildly.
-
Mohammed bin Salman: The new face of Saudi ArabiaUnder the crown prince Mohammed bin Salman, Saudi Arabia's de facto ruler, the kingdom has pursued ambitious reforms to transform itself into a thriving 21st-century economy
